Literature DB >> 30801814

Speech intelligibility in patients with oral cancer: An objective baseline evaluation of pretreatment function and impairment.

Florian Stelzle1, Nicolai Oetter1, Luisa Theresa Goellner1, Werner Adler2, Maximilian Rohde3, Andreas Maier4, Levi Matthies5, Marco Rainer Kesting1, Christian Knipfer5.   

Abstract

BACKGROUND: This study seeks to identify those factors that influence the pre-therapeutic speech intelligibility in patients with oral squamous cell carcinoma (OSCC).
METHOD: A group of 172 patients (125 males, 47 females, mean age = 61 ± 11 a) with different OSCC stages ranging from T1 to T4 and N0 to N2 was examined for their speech intelligibility using a computerized measuring tool, and compared to a healthy reference group (30 males, 10 females, mean age = 59 ± 12 a).
RESULTS: It was found that the pre-therapeutic speech intelligibility in patients with OSCC is decreased when compared to a healthy collective. Two demographic factors that influence speech intelligibility could be identified: sex and age. It was determined that the only disease-related factor that influences speech intelligibility before therapy is the location of the tumor.
CONCLUSION: The results of this study reveal that a preoperative speech intelligibility impairment in patients suffering from OSCC occurs independent of tumor stage, size of the tumor and infiltration status.
© 2019 Wiley Periodicals, Inc.

Entities:  

Keywords:  PEAKS; automatic speech quantification; oral cancer; presurgical; speech intelligibility

Year:  2019        PMID: 30801814     DOI: 10.1002/hed.25527

Source DB:  PubMed          Journal:  Head Neck        ISSN: 1043-3074            Impact factor:   3.147


  1 in total

1.  Validation of an Intelligibility Assessment Tool in an Indian Language for Perceptual Speech Analysis in Oral Cancer Patients.

Authors:  Yogesh Dokhe; Krishnakumar Thankappan; Ridhi Sood; Arya Chandrababu Jaya; Deepak Balasubramanian; Shilpa Chatni; Bibitha Kizhakkevalappil Babu; Sajith Babu; Swapna Sebastian; Shaji Thomas; Paul Sebastian; Subramania Iyer
Journal:  Indian J Surg Oncol       Date:  2020-09-19
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.